Fresenius continues steady growth:
This article was originally published in Clinica
First-quarter turnover at Fresenius rose 13% to DM 534 million ($368 million), almost entirely due to foreign business. Revenue breakdown by division was: dialysis technology 56%; pharmaceuticals 33%; critical care and diagnostics 7%; and project business 4%. Net income was DM 15 million, up 19% compared with 1994. Fresenius expects total sales in 1995 to rise 10%.
You may also be interested in...
COVID-19 Vaccines: ACIP’s Allocation Proposal Prioritizes Long-Term Care Residents, Essential Workers
First group to receive vaccine would comprise health care personnel and residents of long-term care facilities; next in line are non-health care essential workers, who would take priority over adults with high-risk medical conditions and those ages 65 years and older, according to the CDC advisory committee’s proposed allocation framework.
Azar says ACIP’s prioritization recommendations should carry weight, but states will be final arbiter of who is vaccinated.
Sanofi R&D head John Reed says the company has kept 95% of patients on its nearly 400 clinical trials, started 59 studies, and benefited from its in-house drug supply management.